Hyperglycemia as a Prognostic Factor In Acute Ischemic Stroke Patients

Background: Hyperglycemia is encountered in 20% to 40% of acute stroke patients, with or without a pre-morbid diagnosis of diabetes mellitus. Hyperglycemia is a risk factor for infarct expansion and poor outcome through the first 72 hours of onset in both diabetics and non-diabetics patients. This study was done to evaluate the glycemic status after acute ischemic stroke and assess its rule in influencing stroke outcome as regards the duration of hospital stay, motor deficit and mortality.

Methods: This retrospective study was conducted in Elzaiton specialized hospital from June 2016 to June 2017on 80 patients after approval of local medical ethical committee. Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms were included and divided into two groups, controlled group (Random blood suger not more than 150 mg/dl) and uncontrolled group ( Random blood suger more than 150 mg/dl). All patients were evaluated for GCS as a primary outcome and for hemorrhagic transformation, hospital stay duration, mechanical ventilation, need for vasopressors,hospital stay and mortality as secondary outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Ischemic Stroke Patients

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hanaa El Gendy

Cairo, Ain Shams University Specialized Hospital, Egypt

About this study

Patients and Methods This study was prospective study conducted in Elzaiton specialized hospital and Ain Shams University from june2016 to June 2017on 80 patients after approval of local medical ethical committee

All patients was subjected to the following

Full clinical history …age, sex, weight and medical history
GCS and motor deficit
Random blood glucose level at admission and 4-6 times daily during hospital stay
HbA1c on admission
Hemodynamic monitoring
Duration of hospital stay
Thirty day mortality
Other laboratory investigation to rule out other similar cause
Follow up hemorrhagic transformation Study tools: Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms will be evaluated.

On ICU admission the random blood sugar was recorded and categorized to less than 150mg/dl (accepted) and more than 150mg/dl(not controlled). Also serial Random blood sugar daily was recorded and categorized to accepted or good control if less than 150mg/dl and not controlled if more than 150mg/dl.

Patients were divided into 2 groups Patients with accepted random blood sugar at admission and controlled blood sugar during hospital stay.

Patients with increased random blood sugar at admission and poor blood sugar control during hospital stay.

These data were collected and patients were observed as regards duration of hospital stay,hemorrhagic transformation, hospital stay duration and 30-days mortality

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age: 40-70years
Sex: Any sex
Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms were evaluated.

Exclusion criteria

Subdural heamatoma, metabolic causes or transient ischemic attack
Sub arachnoid heamorrage
Heamorragic stroke
Patients with major comorbidities at admission as end stage liver disease, end stage renal disease and malignant hypertension
Patients with hyperglycemia at admission and controlled blood sugar during hospital stay
Patients with DKA or hypoglycemia (RBS less than 70 mg dl)

Treatment and study plan

observational study

Other

observational study

Primary outcomes

GCS

Time frame: 30 days

GCS was assessed for 30 days

Secondary outcomes

30 days mortality

Time frame: 30 days

30 days mortality

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Dec 12, 2019
Registry last updated: Feb 4, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed